{
    "clinical_study": {
        "@rank": "117675", 
        "arm_group": {
            "arm_group_label": "Type 2 diabetic patients", 
            "arm_group_type": "Experimental", 
            "description": "Type 2 diabetic patients, naive to treatment, and not well controlled by diet (glycate hemoglobin > 6.5%, and < 9.0%) will be instructed to take metformin, followed by metformin plus pioglitazone, and then metformin plus pioglitazone plus sitagliptin."
        }, 
        "brief_summary": {
            "textblock": "The treatment of type 2 diabetes mellitus often requires the use of one or more hypoglycemic\n      agents to reach the adequate glycemic control. The aim of the study is to evaluate the\n      effects of a triple therapy with metformin, pioglitazone and sitagliptin on glycemic\n      variability compared to metformin monotherapy, and compared to a combination of metformin\n      and pioglitazone. To assess glycemic variability a continuous glucose monitoring system will\n      be used."
        }, 
        "brief_title": "Triple Therapy in Type 2 Diabetic Patients", 
        "completion_date": {
            "#text": "June 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "In an estimated temporal space of about 3 years, 64 not well controlled, type 2 diabetic\n      patients will be recruited.\n\n      Patients will be instructed to take metformin 500 mg three times a day for the first three\n      months, then pioglitazone 15 mg twice a day will be added for further three months, and\n      finally sitagliptin 100 mg once a day will be added for the last three months. At the\n      baseline, and every three months a continuous glucose monitoring system will be performed.\n\n      At any stage of the study, if the value of glycated hemoglobin reach the desired goal\n      (<6.5%), participation in the study will be stopped and the patient will not be subjected to\n      further adjustments of hypoglycemic therapy or additional continuous monitoring glucose.\n\n      After collection of written informed consent, the following data will be collected:\n\n        -  History: type of diabetes, comorbidities, current medication, duration of diabetes and\n           complications, voluptuary habits such as tobacco smoke (both number of packets/year and\n           n\u00b0 packets/day), alcohol consumption, coffee consumption, physical activity.\n\n        -  Physical exam, general anthropometric parameters such as weight, height, circumference,\n           body mass index, waist-hip ratio, and blood pressure.\n\n        -  Assessment of glycemic variability every three months using a continuous glucose\n           monitoring system.\n\n        -  Collection of blood and urine samples to assess: glycated hemoglobin, fasting plasma\n           glucose (FPG), post-prandial glucose (PPG), fasting plasma insulin (FPI), HOMA-index\n           (HOMA-IR and HOMA-\u03b2), high sensitivity C-reactive protein (hs-CRP), total cholesterol,\n           LDL-cholesterol, HDL-cholesterol, tryglicerides, lipoprotein (a) [Lp(a)],\n           metalloproteinase-2 (MMP-2), metalloproteinase-9 (MMP-9), soluble adhesion molecules\n           (sICAM-1, sVCAM-1), sE-selectin, adiponectin (ADN), complete urinalysis, 24-hour\n           microalbuminuria."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  type 2 diabetic patients\n\n          -  naive to therapy\n\n          -  glycated hemoglobin > 6.5 and < 9.0 %\n\n        Exclusion Criteria:\n\n          -  hepatic and renal diseases\n\n          -  recent cardiovascular diseases\n\n          -  previous pancreatitis\n\n          -  history of cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01895569", 
            "org_study_id": "20120021548"
        }, 
        "intervention": [
            {
                "arm_group_label": "Type 2 diabetic patients", 
                "description": "Metformin will be added to therapy for the first threre months.", 
                "intervention_name": "Metformin", 
                "intervention_type": "Drug", 
                "other_name": "500 mg three times a day"
            }, 
            {
                "arm_group_label": "Type 2 diabetic patients", 
                "description": "In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin, pioglitazone will be added.", 
                "intervention_name": "Pioglitazone", 
                "intervention_type": "Drug", 
                "other_name": "15 mg twice a day"
            }, 
            {
                "arm_group_label": "Type 2 diabetic patients", 
                "description": "In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.", 
                "intervention_name": "Sitagliptin", 
                "intervention_type": "Drug", 
                "other_name": "100 mg once a day"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Pioglitazone", 
                "Sitagliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "July 3, 2013", 
        "location": {
            "contact": {
                "email": "giuseppe.derosa@unipv.it", 
                "last_name": "Giuseppe Derosa, MD, PhD"
            }, 
            "contact_backup": {
                "email": "pamelamaffioli@hotmail.it", 
                "last_name": "Pamela Maffioli, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Pavia", 
                    "country": "Italy", 
                    "zip": "27100"
                }, 
                "name": "IRCCS Policlinico S. Matteo Foundation"
            }, 
            "investigator": [
                {
                    "last_name": "Giuseppe Derosa, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Pamela Maffioli, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Effects on Glycemic Variability and Glyco-metabolic Control of Metformin, Pioglitazone and Sitagliptin in Type 2 Diabetic Patients", 
        "other_outcome": {
            "description": "Insulin-resistance parameters will be assessed using HOMA-index (HOMA-IR and HOMA-\u03b2).", 
            "measure": "Insulin-resistance parameters", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "overall_contact": {
            "email": "giuseppe.derosa@unipv.it", 
            "last_name": "Giuseppe Derosa, MD, PhD"
        }, 
        "overall_contact_backup": {
            "email": "pamelamaffioli@hotmail.it", 
            "last_name": "Pamela Maffioli, MD"
        }, 
        "overall_official": {
            "affiliation": "IRCCS Policlinico San Matteo Foundation", 
            "last_name": "Giuseppe Derosa, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Italy: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Glycemic variability will be assessed at the baseline, and every three months, using a continuous glucose monitoring system.", 
            "measure": "Glycemic variability", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01895569"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Pavia", 
            "investigator_full_name": "Giuseppe Derosa", 
            "investigator_title": "MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Glyco-metabolic control will be assessed evaluating glycated hemoglobin, fasting plasma glucose and post-prandial glucose.", 
            "measure": "Glyco-metabolic control", 
            "safety_issue": "Yes", 
            "time_frame": "9 months"
        }, 
        "source": "University of Pavia", 
        "sponsors": {
            "collaborator": {
                "agency": "IRCCS Policlinico S. Matteo", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Pavia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}